Beursonline.nl

positivo73 18 juli 2005 10:35

0

even weer omhoog zetten voor nieuwe beleggers.
m.v.g.Willem

ludwig mack 27 juli 2005 11:27

0

idem !

[verwijderd] 27 juli 2005 11:30

0

Intressant leesvoer

---------------------------------------------------------------------------------
www.checkbiotech.org/root/index.cfm?f...

Using goats to solve autoimmune diseases

Monday, July 25, 2005
By Katharina Schoebi, Checkbiotech

People suffering from autoimmune disorders, such as rheumatoid arthritis, psoriasis or multiple sclerosis, may be aided in the future: Merrimack Pharmaceuticals, Inc. is developing MM-093, a recombinant version of human á-Fetoprotein (hAFP), which is believed to have a beneficial impact on many autoimmune disorders. The twist is that Merrimack’s strategic manufacturing partner, GTC BIOTHERAPEUTICS, INC, is producing MM-093 in the milk of transgenic goats.

The glycoprotein called human á-Fetoprotein (AFP) is constitutively produced at low levels throughout life. In the fetus’ blood, there are about five microgram AFP per milliliter. Since fetal AFP enters the maternal bloodstream, pregnant women have a maximal concentration of 300 – 500 nanogram per milliliter during the third trimester of pregnancy. It is known that during pregnancy, especially during the last three months, several autoimmune disorders, such as multiple sclerosis, rheumatoid arthritis and psoriasis, go into remission.

Therefore, researchers have examined AFP for its immunomodulatory properties. The effect of AFP on rheumatoid arthritis, multiple sclerosis, myasthenia gravis and thyroiditis has been well documented in animal experiments and provides a rationale for testing MM-093 in humans. However, human clinical testing requires a great deal of properly constructed and biologically active protein. Therefore, there is need for a production system that can cost-effectively generate large amounts of MM-093.

Several experiments have shown, that recombinant AFP produced in systems such as Escherichia coli, baculovirus and yeast, has immunomodulatory properties. However, the molecule is quite large and complicated and recovery of a sufficient yield of properly folded protein can be problematic in certain systems – for example, E. coli. Thus, there was a need to investigate a novel production system and Merrimack chose to investigate the transgenic goat system with GTC Biotherapeutics (previously Genzyme Transgenics) of Framingham, Massachusetts.

GTC Biotherapeutics has developed the transgenic goat technology as a cost-effective alternative for the production of complex proteins on a large scale. The goats produce the protein of interest in their milk – the goats are maintained on a high-tech farm using state-of-the-art animal husbandry techniques and procedures and milked using standard processes that would be employed on a dairy farm.

Merrimack then developed a process to purify MM-093 out of the goat milk and performed a battery of tests to demonstrate that it was highly comparable to human AFP (M. H. Parker et al,. 2004. Purification and characterization of recombinant human alpha-fetoprotein expressed in the milk of genetically modified goats. Protein Expression and Purification. 38:177-183.)

Once the goat milk is filtered to remove milk fat and milk proteins – essentially creating “extreme” skim milk – the purification process is very similar to purification of proteins from any other production system. The process involves standard chromatography-based purification steps that remove contaminants. The development team demonstrated that MM-093 and hAFP were virtually identical using several analytical techniques to evaluate primary, secondary and tertiary structure. In addition, the biological activity of MM-093 produced in transgenic goats was tested using cell binding assays and in animal models of disease and MM093 was determined to be biological active.

Merrimack has tested MM-093 produced in transgenic goats in Phase 1 human clinical trials and is currently testing MM-093 in a large clinical trial of rheumatoid arthritis patients who do not receive adequate relief from current therapies. Like most other therapeutic proteins, MM-093 is administered to these patients by a subcutaneous injection.

While sometimes joked about, it is important to note that it is not possible to use goat milk or goat cheese therapeutically, as the management of the goats, and the goat products, are strictly regulated by multiple government agencies. The goats are handled with the utmost care and neither the goats nor their milk will ever end up in the food chain.

[verwijderd] 28 juli 2005 15:58

0

GTC Biotherapeutics and Scancell Collaborate on SC101 Antibody

biz.yahoo.com/bw/050728/285572.html?.v=1

Press Release Source: GTC Biotherapeutics, Inc.

GTC Biotherapeutics and Scancell Collaborate on SC101 Antibody
Thursday July 28, 9:28 am ET

FRAMINGHAM, Mass. and NOTTINGHAM, U.K.--(BUSINESS WIRE)--July 28, 2005--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and Scancell Limited ("Scancell") announced that they have signed a collaboration agreement to evaluate the expression of Scancell's SC101 anti-cancer monoclonal antibody (MAb) using GTC's transgenic production platform. Their agreement contemplates that both companies will work toward the establishment of a definitive agreement for the potential clinical development of SC101.
ADVERTISEMENT

"We look forward to demonstrating the value offered by transgenic technology for the production of antibody products such as SC101," noted Gregory Liposky, GTC's Senior Vice President, Operations. "GTC's technology offers significant advantages for the development of proteins that are projected to be required in large commercial production quantities, when approved, and we believe we can assist Scancell in realizing that potential value."

Commenting on the agreement, Michael Capaldi, Chief Executive Officer of Scancell, said: "We are very pleased to be working with GTC. This agreement offers Scancell the opportunity to establish development of what we believe will be a very large scale product at significantly lower capital investment."

SC101 is a MAb that targets Lewis y/b. Lewis y/b is a cell surface carbohydrate blood group antigen whose expression is very low in normal tissue but is over-expressed on breast, colorectal, endometrial, kidney, lung, pancreas and stomach tumours. Mouse antibodies recognizing Lewis y/b have induced tumor cell death and inhibited growth of various tumor lines. In animal studies, tumor growth was inhibited by anti-Lewis y/b antibodies alone, and especially when combined with 5-fluorouracil, an antimetabolite that disrupts cancer cell growth.

About GTC Biotherapeutics

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the prospects for anticipated expression of SC101 in a transgenic production system and for a definitive agreement with Scancell for further development of transgenic production for SC101. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the risks and uncertainties inherent in the development of transgenic expression of compounds and the actions of collaboration partners. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law. GTC specifically disclaims responsibility for information describing Scancell, its business and SC101, other than the collaboration with GTC.

About Scancell

Scancell Ltd is a company focused on the discovery and development of products that harness the immune system in a unique way to treat or prevent cancer. The Company, which currently employs 12 individuals, has secured GBP 4.6million of private equity and commercial funding. The Company has built an early stage product pipeline based upon two platforms: directly killing MAbs ('killer' MAbs) and its patent protected ImmunoBody® vaccine platform. 'Killer' MAbs are raised against 'cocktails' of primary human tumours resulting in MAbs that recognize clinically relevant targets. The Company screens for MAbs that directly kill tumour cells (i.e. without the need for antibody-dependant cellular cytotoxicity (ADCC) or complement mediated cytotoxicity (CDC)) and have an additive and/or synergistic killing effect in the presence of chemotherapeutics. Scancell has three such products in pre-clinical development and a number of further 'killer' MAbs in research. Scancell's ImmunoBody® technology uses human antibodies as vectors to target clinically relevant T-cell epitopes to activated dendritic cells via the high affinity CD64 receptor thereby initiating cellular immunity against cancers or chronic infectious diseases. For more information about Scancell visit www.scancell.co.uk

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects.

Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Scancell is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

--------------------------------------------------------------------------------
Contact:
GTC Biotherapeutics, Inc.
Thomas E. Newberry, US 508-370-5374
or
Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
Francesca DeVellis, US 617-577-8110
or
Scancell Limited
Michael Capaldi, UK 0115 912 4311

--------------------------------------------------------------------------------
Source: GTC Biotherapeutics, Inc.

[verwijderd] 1 augustus 2005 15:28

0

GTC BIOTHERAPEUTICS RECEIVES NOTICE OF ALLOWANCE ON PURIFICATION PATENT

FRAMINGHAM, MA – August 1, 2005 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that the United States Patent and Trademark Office has issued a notice of allowance for the claims in its patent application 10/635,117 covering tangential flow filtration technology. These claims provide GTC with a unique position in the use of this technology to recover recombinant therapeutic proteins that are expressed in the milk of transgenic animals. The patent that issues from this application will expire in 2023.

Tangential flow filtration is an initial product recovery step that removes fats and other colloidal proteins such as casein from milk containing the target protein of interest. This approach also allows for the significant reduction in volume of the milk while yielding a material that can be aseptically processed. The resulting partially purified intermediate bulk product is more stable than unprocessed milk and can be stored for extended periods either refrigerated or frozen. The intermediate bulk product is then taken through additional purification steps, typically chromatography, to obtain a highly purified form of the desired therapeutic protein.

GTC is able to produce a therapeutic protein in an animal’s milk through a process known as transgenic technology. GTC couples the gene expressing a specific protein with a specific milk protein promoter gene and incorporates it into an animal’s genome such that the protein is expressed during lactation. This approach has been demonstrated to enable the production of therapeutic proteins that are difficult to express in traditional production methods. For products that can be expressed in conventional recombinant technology, transgenic technology has significantly lower capital requirements to establish large volume capacity.

About GTC Biotherapeutics, Inc.

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding GTC’s patent position. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the uncertainties associated with intellectual property. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.

[verwijderd] 2 augustus 2005 13:27

0

Nieuwe institutional Holdings per 30 juni 2005.

Click on the column header links to resort ascending () or descending ().

Owner Name
Select a name below for more information.
Date Shares Held Change(Shares)% Change(Shares)Value($1000)
VANGUARD GROUP INC 6/30/2005 475,989 (29,200) (5.78%) $833

TIAA CREF INVESTMENT... 6/30/2005 37,254 (13,802) (27.03%) $65

NORDEA INVESTMENT MA... 6/30/2005 51,000 (20,000) (28.17%) $89

DIMENSIONAL FUND ADV... 6/30/2005 1,028,199(67,338) (6.15%) $1,799

BANKMONT FINANCIAL C... 6/30/2005 15,000 0 0.00% $26

ludwig mack 4 augustus 2005 13:02

0

Please see an overview of the market for ATryn, an overview of where other products for ATIII are available and the names. I am working this overview adding current commercial prices where I can find them. Mind that all current products are plasma derived.

Greetings Norman

EUROPE

Country Population[million] Prod. available
Austria 8.2 Atenativ, Thrombhibin, Antimbin P, Kybernin
Belgium 10.4 -
Cyprus 0.8 -
Czech Rep. 10.2 Kybernin
Denmark 5.4 Atenativ
Estonia 1.4 -
Finland 5.2 Atenativ
France 59.6 Aclotine
Germany 82.5 Atenativ, ATIII, Kybernin
Greece 11.0 Atenativ, Kybernin
Hungary 10 Atenativ, Kybernin
Ireland 4 -
Italy 57.3 Atenativ, Anbin, Kybernin
Latvia 2.4 -
Lithuania 3.7 -
Luxembourg 0.4 -
Malta 0.4 -
Poland 38.8 -
Portugal 10.4 -
Slovakia 5.4 -
Slovenia 2 -
Spain 40.7 Atenativ, Anbin, Kybernin
Sweden 8.9 Atenativ
The Netherlands 16.2 Atenativ
United Kingdom 58.8 Kybernin

EUROPE CANDIDATE MEMBERS
Country Population Products available
Bulgaria 8.2 -
Croatia 4.5 -
Romania 22.3 -
Turkey 66.6 -

OTHER EUROPEAN COUNTRIES
Country Population Products available
Albania 3.1
Andorra 0.1 -
Belarus 10.2 -
Bosnia 4 -
Macedonia 2 -
Iceland 0.3 -
Liechtenstein 0.0 -
Moldova 4.4 -
Monaco 0.0 -
Norway 4.5 Atenativ
Russia 146.9 -
San Marino 0.0 -
Serbia-Montenegro 10,6 -
Switserland 7.4 Atenativ, Kybernin
Ukraine 50.50 -
Vatican City 0.0 -

OTHER NON EUROPEAN MARKETS
Country Population Products available
Brazil 170.1 Kybernin
Australia 18.9 Thrombotrol
New Zealand 3.9 Thrombotrol
Canada 31.1 Thrombate III
Hong Kong 7 Thrombate III
USA 278.4 Thrombate III
Japan 126.7 Neuart

jasssie - 3-8-05, 16:05 | Reageer | Quote | Zoek | Aanbevolen: 0

*1 The average is based on the formule : units required (IU) = [desired AT-III level (%) - baseline AT-III level (%)]/1.4 x body weight (kg). where the average body weight (man and woman) has been set to 70 kg and the desired level 120% and the baseline level at 50 %.
The baseline is normally varying between the 40 and 60 % of the normal level. Thus, if a 70 kg individual has a base-line AT-III level of 50%, in order to increase plasma AT-III to 120%, the initial THROMBATE III dose would be [(120-50) x 70]/1.4 = 3500 IU total.

*2 AT-III deficiency is found in approximately 1 in 2,000 to 5,000 persons.

jasssie - 3-8-05, 16:06 | Reageer | Quote | Zoek | Aanbevolen: 0

Marketprices found so far are in the range of 350 - 440 EUR per 1000 units.

An average of 3500 units will be needed (see explaination in previous message).

This will give a average of 1225 to 1540 per treatment. It is expectable that compared with the plasma the recombinant version can be sold with a small premium as it is safer then plasma.

Marketprice sources:
www.sante.gouv.fr/htm/dossiers/retroc... (france)
www.giofil.it/offline/SObttlth.htm (italy)
www.hidoctor.com.br/tabela/?session=&... =win (brazil)
www.iespana.es/inspeccion-uvmi1/inde1... (spain , 2000 !, used to be 390 Euro, now 310 Euro, possibly this is the subsidized vendor price)
www.oddb.org/en/generika/search/state... (switserland)

positivo73 5 augustus 2005 14:08

0

Even weer bovenaan zetten. Er zijn een hoop mensen met vragen die ze hier kunnen vinden.
m.v.g.Willem

ludwig mack 8 augustus 2005 23:44

0

GTC Biotherapeutics Announces Private Placement of Common Stock and Warrants
Monday August 8, 7:58 am ET

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Aug. 8, 2005--GTC Biotherapeutics, Inc. (Nasdaq: GTCB - News; "GTC") announced today that it has entered into definitive agreements with certain institutional investors for a private placement of Common Stock and Common Stock Purchase Warrants. GTC has agreed to sell an aggregate of approximately 4.57 million shares of Common Stock at $1.75 per share. The investors will also receive 5-year warrants to purchase an aggregate of approximately 1.8 million additional shares of GTC's Common Stock at an exercise price of $2.68 per share.
Rodman & Renshaw, LLC acted as exclusive placement agent for the securities sold in this transaction.

The proceeds of the financing are expected to be used for general corporate purposes, including funding GTC's ongoing clinical trial activities and preparations for commercialization of ATryn®, pending review of the Market Authorization Application (MAA) for ATryn® by the European Medicines Agency (EMEA).

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from registration requirements. GTC has agreed to file a resale registration statement on Form S-3 within 20 days after the closing of the transaction for purposes of registering the shares of Common Stock, as well as the shares of Common Stock underlying the warrants, acquired by these investors.

ludwig mack 8 augustus 2005 23:59

0

Recombinant Human Antithrombin Demonstrates Therapeutic Potential in Endotoxemia Model of Sepsis
Monday August 8, 9:05 am ET

FRAMINGHAM, Mass. and SYDNEY, Australia--(BUSINESS WIRE)--Aug. 8, 2005--Today, at the 20th Congress of the International Society of Thrombosis and Haemostasis in Sydney, Australia, Dr. Judith Leitner, working with Dr. Bernd Jilma's team at the Medical University of Vienna, presented the results of a study that described the therapeutic potential of recombinant human antithrombin, supplied by GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB), in a human model of sepsis. This physician-sponsored trial showed that supra-physiological levels of antithrombin without concomitant heparin have potent dose-dependent anticoagulant effects and anti-inflammatory properties in human experimental endotoxemia.
ADVERTISEMENT

Severe sepsis still carries a high mortality rate despite advances in intensive care medicine and antimicrobial therapy. Every year, more than 750,000 people in the United States develop severe sepsis, a syndrome characterized by an overwhelming systemic response to infection, which can lead to organ dysfunction and ultimately death. Approximately 215,000 people in the US die from severe sepsis every year. The death rate can be as high as 60% for people with underlying medical problems.

Three natural anticoagulants have been tested in large phase III trials in sepsis: recombinant human activated Protein C, tissue factor pathway inhibitor and antithrombin. In all three trials, concomitant administration of heparin could have compromised clinical efficacy of the drugs under investigation. This study team hypothesized that antithrombin infused without concomitant heparin would have dose-dependent anticoagulant properties and potentially decrease endotoxin induced cytokine production.

Results in Coagulation and Inflammation

Coagulation: In vivo thrombin formation decreased in a dose dependent fashion as measured by prothrombin fragment, thrombin antithrombin complexes (TAT) and D-dimer.

Inflammation: Infusion of recombinant human antithrombin rapidly decreased neutrophil and monocyte counts before endotoxin challenge, demonstrating a direct interaction with these leukocyte subsets. Antithrombin treatment significantly decreased peak interleukin-6 (IL-6) release by 40%.

Study Design

The study was a randomized, double-blind and placebo-controlled trial, consisting of three parallel groups totaling 30 healthy male subjects. Volunteers were randomly assigned to receive either a bolus primed continuous infusion of recombinant human antithrombin at 500% or 200% of normal antithrombin level or an equal volume of placebo (0.9% NaCl) over 4 hours. Immediately after the recombinant human antithrombin bolus infusion, an intravenous bolus of 2 ng/kg National Reference Endotoxin (LPS, Escherichia coli; USP, Rockville, MD) was given to all subjects.

About GTC Biotherapeutics

GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATryn®, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATryn® in patients with a hereditary antithrombin deficiency. In addition to the ATryn® program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, www.gtc-bio.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including the potential for further study and eventual use of recombinant human antithrombin in the treatment of sepsis or endotoxemia. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports as filed with the Securities and Exchange Commission, including the risks and uncertainties inherent in the performance of demonstration studies and the clinical development of therapeutics. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.

--------------------------------------------------------------------------------
Contact:
GTC Biotherapeutics, Inc.
Thomas E. Newberry, 508-370-5374
Vice President, Corporate Communications
or
Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
Francesca DeVellis, 617-577-8110

--------------------------------------------------------------------------------
Source: GTC Biotherapeutics, Inc.

[verwijderd] 10 augustus 2005 23:10

0

morgen

Thu Aug 11 2005 10:00 AM Q2 2005 GTC Biotherapeutics, Inc. Earnings Conference Call

ludwig mack 18 augustus 2005 10:51

0

op voorpagina !

$rob$ 18 augustus 2005 12:06

0

quote:
ludwig mack schreef:
op voorpagina !

huuuh? wie, wat, waar?

positivo73 22 augustus 2005 13:12

0

een klein tikje naar boven

ludwig mack 26 augustus 2005 12:15

0

een grote tik naar boven !

[verwijderd] 26 augustus 2005 12:48

0

Hoe zo naar boven??

positivo73 31 augustus 2005 16:41

0

voor de mensen die aan het twijfelen zijn geraakt.
m.v.g.Willem

[verwijderd] 1 september 2005 16:00

0

Hoog Sammie, kijk omhoog Sammie

[verwijderd] 1 september 2005 16:21

0

Jammer dat die Dollar in elkaar stort.

[verwijderd] 4 september 2005 21:49

0

Met dank aan Groen07

Biotherapeutics: Kleine reus op komst?

De Biotechfondsen staan in de picture, al lange tijd is dat al zo ... Het is nu soms zoeken naar aandelen die kans bieden op een sprong omhoog met waardes die 100 tot 200% hoger staan .. Dit kan door een overname of door nieuwe producten ... Bij Biotherapeutics (Ticker GTCB) zou zoiets wel eens kunnen ... Zoiets is noot zeker maar aan het koersverloop te zien zou het kunnen ... Een analyse van dit fonds ....

Bioteherapeutics een kleine reus op komst?

Het verloop van dit aandeel toont aan dat er mogelijk iets op komst is, de rally vanaf de 85 cent tot de top op 2,39 dollar begin deze maand spreekt natuurlijk in het voordeel van die gedachte. We zien de koers nu wat terugvallen tot rond de 1,70 dollar na een afkoelingsperiode maar de daar komen enkele belangrijke steunpunten samen. Het zou kunnen dat het fonds daar enkele dagen tot weken uitrust met mogelijkheden tot de 1,85~1,9 aan de bovenkant en de 1,6~1,65 dollar aan de onderkant. Die steun rond de 1,60 dollar lijkt me in ieder geval op korte termijn vrij betrouwbaar omdat daar de horizontale lijn uitkomt samen met het 200-daags gemiddelde. Die steun dus in de gaten houden.

Aan de bovenkant waar de grotere kansen liggen zien we boven de zone 1,85~1,9 dollar veel ruimte, eerst tot de top net onder de 2,4 dollar waar er al 50 cent winst kan worden geboekt en later bij een uitbraak mogelijkheden tot de 3, 4 of 5 dollar. Als het fonds de weg omhoog heeft gevonden dan ziet het er stevig uit.

De vraag is nu uiteraard alleen nog of het gaat om een fundamentele oorzaak gesteund door een sterke technische drive of als het gaat om een overnamebod. Waar zoiets ligt weet natuurlijk niemand, dat kan tot boven de 5 dollar maar het kan net zo goed 2,5 dollar worden. We zien wel en houden dit fonds in ieder geval goed in de gaten de komende periode.

Onder de 1,4 dollar kan het fonds wel weer inslapen voor een langere tijd, dus ook uw stop in de gaten houden mocht u hierin geïnteresseerd zijn....

www.usmarkets.nl/modules.php?name=New...

BENZ

AEX 878,83 -3,44 -0,39% 18:05


Germany40^	17.925,40	-1,06%
BEL 20	3.883,26	-0,09%
Europe50^	4.911,90	-1,39%
US30^	38.043,99	-0,85%
Nasd100^	17.570,06	-1,24%
US500^	5.063,57	-1,00%
Japan225^	38.318,54	+0,24%
Gold spot	2.293,07	-1,83%
EUR/USD	1,0676	-0,43%
WTI	81,69	-1,22%

Corbion	+2,70%
B&S Group SA	+1,20%
Ahold Delhaize	+1,17%
ForFarmers	+1,04%
OCI	+1,00%

VIVORYON THER...	-13,94%
EBUSCO HOLDING	-5,50%
ACOMO	-4,69%
Air France-KLM	-4,29%
Arcadis	-3,88%

BioPharma « Terug naar discussie overzicht

GTCB samengevat !

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers